Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial

BACKGROUND: As an irreversible, intractable disease with vision loss, glaucoma leads to permanent and progressive damage of visual function. Lowering high intraocular pressure (HIOP) is the first choice for treating glaucoma; however, the control of HIOP is not enough to prevent progressive vison lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongji, Li, Xiang, Zhang, Zongduan, Zeng, Jieping, Dai, Yan, Wang, Chao, Xie, Zhao, Cheng, Lin, Cui, Linru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249294/
https://www.ncbi.nlm.nih.gov/pubmed/32450908
http://dx.doi.org/10.1186/s13063-020-04249-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249294/
https://www.ncbi.nlm.nih.gov/pubmed/32450908
http://dx.doi.org/10.1186/s13063-020-04249-7

Ejemplares similares